Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05734196 · ClinicalTrials.gov registry record · Phase 1
The ENERGY Study: Evaluation of Safety and Tolerability of INZ-701 in Infants With ENPP1 Deficiency or ABCC6 Deficiency
A Phase 1 study of Ectonucleotide Pyrophosphatase/phosphodiesterase1 Deficiency and Pseudoxanthoma Elasticum, sponsored by Inozyme Pharma.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 16
- Enrollment target
- 7
- Study locations
NCT05734196: Recruiting Phase 1 study of Ectonucleotide Pyrophosphatase/phosphodiesterase1 Deficiency and Pseudoxanthoma Elasticum, sponsored by Inozyme Pharma.
NCT05734196 is a Phase 1 study of Ectonucleotide Pyrophosphatase/phosphodiesterase1 Deficiency and Pseudoxanthoma Elasticum that is actively recruiting participants, run by Inozyme Pharma. The registered enrollment target is 16 participants, below the 309-participant average among 4 other Ectonucleotide Pyrophosphatase/phosphodiesterase1 Deficiency trials with a reported enrollment target (95% lower). The trial reports 7 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05734196, a Phase 1 study of Ectonucleotide Pyrophosphatase/phosphodiesterase1 Deficiency and Pseudoxanthoma Elasticum, is actively recruiting participants, sponsored by Inozyme Pharma.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 16 participants
- Enrollment target
- 7
- Study locations
Study Summary
The primary purpose of Study INZ701-104 (the ENERGY study) is to assess the safety and tolerability of INZ-701 in infants with ENPP1 Deficiency or with ABCC6 Deficiency.
Primary Outcome
Treatment-emergent AEs are defined as any AE occurring from the first dose of INZ-701 through 30 days after the last dose of INZ-701.
Conditions Studied
Interventions
- DRUG INZ-701
Study Locations (7)
Other
- Hospital Sant Joan de Déu - Barcelona
- Royal Manchester Children's Hospital - Manchester
California
- Rady Children's Hospital - San Diego
Massachusetts
- Boston Children's Hospital - Boston
Ohio
- Nationwide Children's Hospital - Columbus
Pennsylvania
- The Children's Hospital of Philadelphia - Philadelphia
Utah
- The University of Utah - Salt Lake City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2023-06-25 |
| Est. Completion | 2026-04-01 |
| Phase | Phase 1 |
What NCT05734196 shows while recruiting
NCT05734196 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 16 participants, a relatively small participant target, below the 309-participant average among 4 other Ectonucleotide Pyrophosphatase/phosphodiesterase1 Deficiency trials with a reported enrollment target (95% lower).
The record links to 5 conditions, with Ectonucleotide Pyrophosphatase/phosphodiesterase1 Deficiency appearing as the primary indexed condition, and to 1 intervention - of which INZ-701 is the first listed.
NCT05734196 lists 7 locations in 6 states (Other, California, Massachusetts).
Frequently Asked Questions
What is clinical trial NCT05734196 about?
NCT05734196 is a clinical study titled "The ENERGY Study: Evaluation of Safety and Tolerability of INZ-701 in Infants With ENPP1 Deficiency or ABCC6 Deficiency". The primary purpose of Study INZ701-104 (the ENERGY study) is to assess the safety and tolerability of INZ-701 in infants with ENPP1 Deficiency or with ABCC6 Deficiency.
What is the current status of trial NCT05734196?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2023-06-25. Estimated completion is 2026-04-01.
What conditions does trial NCT05734196 study?
This clinical trial studies the following conditions: Ectonucleotide Pyrophosphatase/phosphodiesterase1 Deficiency, Pseudoxanthoma Elasticum, Autosomal Recessive Hypophosphatemic Rickets, Generalized Arterial Calcification of Infancy, ATP-Binding Cassette Subfamily C Member 6 Deficiency.
What interventions are being tested in trial NCT05734196?
The interventions under investigation include: INZ-701 (DRUG).
Who is sponsoring clinical trial NCT05734196?
This trial is sponsored by Inozyme Pharma, which has 9 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05734196 being conducted?
This trial has 7 study locations across California, Massachusetts, Ohio, Pennsylvania, Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ectonucleotide Pyrophosphatase/phosphodiesterase1 Deficiency
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Evaluation of Safety, Tolerability, and Efficacy of INZ-701 in Adults With ENPP1 Deficiency
COMPLETED · Phase 1
-
ADAPT Study: Long-term Safety Study of INZ-701 in Patients With ENPP1 Deficiency and ABCC6 Deficiency
RECRUITING · Phase 2
-
PROPEL - A Prospective Observational Patient Registry to Evaluate ENPP1 and ABCC6 Deficiency
RECRUITING
-
The ENERGY 3 Study: Evaluation of Efficacy and Safety of INZ-701 in Children With ENPP1 Deficiency
ACTIVE NOT RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02422641 · 16 participants · Phase 2
Prospective Evaluation Of High-Dose Systemic Methotrexate In Patients With Breast Cancer And Leptomeningeal Metastasis
- NCT02851758 · 16 participants · NA
Transplantation of Autologously Derived Mitochondria Following Ischemia
- NCT03291028 · 16 participants
Analysis of Primary and Metastatic Tumors in Patients With Renal Cell Carcinoma and Urothelial Carcinoma
- NCT03425526 · 16 participants · Phase 1
Donor T Cell Therapy in Treating Immunocompromised Patients With Adenovirus-Related Disease
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI